Pharmafile Logo
Pharmafocus logo
Advanced Search

generics

Showing 15 posts of 209 posts found.

Advent reportedly backs out of bid for Pfizer’s Brazil plant

March 23, 2017
Sales and Marketing Brazil, Pfizer, generics

It has been reported that Advent International Corp has pulled out of bidding for Pfizer’s stake in Brazilian generics manufacturer, …

News

Pfizer plant receives FDA warning letter for contamination of medicine

March 1, 2017
Manufacturing and Production Copaxone, Mylan, Pfizer, Teva, generics

The FDA has issued a warning letter to Pfizer after inspectors discovered that the plant did not protect properly against …

News

Insider Interview: BGMA Director Warwick Smith disputes recent generic price increase claims

February 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Warwick Smith, bgma, generics

Warwick Smith, Director of the British Generic Manufacturer’s Association (BGMA), discusses the recent data suggesting generic drug prices in the …

Feature
medication

Generic version of top-selling lung cancer drug hits Chinese market

February 20, 2017
Sales and Marketing China, generics

A generic version of AstraZeneca’s Iressa (gefitinib) has been released onto the Chinese market, named Yiruike. The generic undercuts the …

News
pills

The future of generic drugs and strategies for commercial success

February 17, 2017
Medical Communications generics

GBI Research examines whether the US continue to dominate the global generic drug market.

News
lillycorporatehq

Lilly three strikes in three years not out in Teva patent challenge

January 13, 2017
Medical Communications, Sales and Marketing Eli Lilly, Teva, generics, lilly, patent

Eli Lilly has successfully won a major patent case against Teva Pharmaceuticals, with the case being decided at the US …

News

Mylan ends 2016 with spate of generics

January 3, 2017
Manufacturing and Production, Sales and Marketing Mylan, generics, launch

Mylan ended a difficult year for itself by releasing a rash of generics into the market, ending the year strongly …

News
teva

CEO of Teva’s Generics Medicines Group steps down

December 6, 2016
Manufacturing and Production, Medical Communications Teva, generics

Sigurdur Olafsson will step down in the first quarter of 2017 as president and CEO of Teva’s Global Generic Medicines …

News
shutterstock_57369385

Biosimilars and Generics: A no-brainer for treatment?

November 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, generics

The industry is poised on the potential widespread adoption of many revolutionary technologies; foremost among them are biosimilars and generics, …

Feature
teva_copy

Teva sets out to delay generic competitor to Copaxone

October 31, 2016
Sales and Marketing Copaxone, Teva, Teva Pharmaceutical, generics

Teva Pharmacetuical, the Israel-based pharmaceutical company, submitted a document to the FDA on 30 October; the document outlines the differences …

News
teva_copy

Teva completes $40 billion acquisition of Actavis Generics

August 3, 2016
Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics

Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …

News
astrazeneca_crestor_rosuvastatin_40mg

AstraZeneca loses legal bid to block Crestor generics

July 20, 2016
Research and Development, Sales and Marketing AstraZeneca, Crestor, FDA, generics, legal

A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …

News
teva_copy

Teva sells $15 billion in bonds to fund Allergan generics deal

July 19, 2016
Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics

Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …

News
teva_copy

Mayne Pharma to buy a portfolio of Teva’s generic drugs for $652 million

June 29, 2016
Research and Development, Sales and Marketing Allergan, Deals, Mayne Pharma, Teva, generics, merger and acquisition

Australia’s Mayne Pharma Group Ltd (ASX: MYX) said it will acquire US generic products from Israel-based drugmaker Teva Pharmaceuticals (NYSE: …

News
teva_copy

Impax to acquire Teva, Allergan generic drugs for $586 million

June 22, 2016
Research and Development, Sales and Marketing Allergan, Impax, Teva, generics

Impax Laboratories (NASDAQ: IPXL) has announced that it has entered into agreements with Teva and affiliates of Allergan to acquire …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024